


Replication, Protease, & Entry Inhibitors Predominate*

Most are vs. Coronaviruses and Orthomyxoviruses


% Clinical Phase Antiviral Compound/Indications by Virus Target and Virus Family (N=80)



*As of November 16, 2023; Clinical Phase includes Ph 1-4 and Approved

Entry Inhibitors* by Viral Disease and Phase of Development


Phase of Development: Phase 1-4



*As of November 16, 2023; Attachment, Capsid (Rhinovirus), Fusion, Viroporin

Protease Inhibitors* by Viral Disease and Phase of Development


Phase of Development: Phase 1-4



*As of November 16, 2023; Mpro (Coronavirus and Enterovirus)

Replication Inhibitors* by Viral Disease and Phase of Development


Phase of Development: Phase 1-4



*As of November 16, 2023; Polymerase, Endonuclease, Replicase, DENV NS4B

Assembly/Release Inhibitors* by Viral Disease and Phase of Development


Phase of Development: Phase 1-4



*As of November 16, 2023; Neuraminidase

Ribavirin and Combinations* by Viral Disease and Phase of Development

Phase of Development: Phase 1-4



*As of November 16, 2023



INTREPID ALLIANCE
INTERNATIONAL READINESS FOR PREVENTING INFECTIOUS VIRAL DISEASE

Interested
in engaging
with us?

For more information, contact
nina@intrepidalliance.org.

 intrepidalliance.org

 [linkedin.com/company/intrepid-alliance](https://www.linkedin.com/company/intrepid-alliance)